Invention Grant
- Patent Title: Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer
-
Application No.: US16322964Application Date: 2017-08-03
-
Publication No.: US11319376B2Publication Date: 2022-05-03
- Inventor: Frank J Calzone
- Applicant: REMD Biotherapeutics, Inc.
- Applicant Address: US CA Camarillo
- Assignee: REMD Biotherapeutics, Inc.
- Current Assignee: REMD Biotherapeutics, Inc.
- Current Assignee Address: US CA Camarillo
- Agency: Craig A Crandall, APC
- Agent Craig A Crandall
- International Application: PCT/US2017/045390 WO 20170803
- International Announcement: WO2018/027084 WO 20180208
- Main IPC: A61P35/00
- IPC: A61P35/00 ; A61K31/4375 ; A61K31/4439 ; A61K31/4545 ; A61K31/517 ; A61K31/519 ; A61K31/5377 ; C07K16/28 ; A61K39/395 ; A61K39/00
Abstract:
The present disclosure relates to combination therapy methods of treating a subject having cancer, comprising administering to the subject a) an effective amount of a pharmaceutical composition comprising a phosphatidylinositol 3-kinase (PI3K) pathway inhibitor, or a pharmaceutically acceptable salt thereof, and b) an effective amount of a pharmaceutical composition comprising a glucagon receptor antagonist.
Public/Granted literature
- US20190169300A1 COMBINATION OF GLUCAGON RECEPTOR ANTAGONISTS AND PI3K PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER Public/Granted day:2019-06-06
Information query
IPC分类:
| A | 人类生活必需 |
| A61 | 医学或兽医学；卫生学 |
| A61P | 化合物或药物制剂的特定治疗活性 |
| A61P35/00 | 抗肿瘤药 |
